Allele-specific inhibition of rhodopsin with an antisense oligonucleotide slows photoreceptor cell degeneration

Investigative Ophthalmology and Visual Science

Volumn 56, Issue 11, 2015, Pages 6362-6375

  Murray, Susan F ^a   Jazayeri, Ali ^a   Matthes, Michael T ^b   Yasumura, Douglas ^b   Yang, Haidong ^b   Peralta, Raechel ^a   Watt, Andy ^a   Freier, Sue ^a   Hung, Gene ^a   Adamson, Peter S ^c   Guo, Shuling ^a   Monia, Brett P ^a   Lavail, Matthew M ^b   McCaleb, Michael L ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

AdRP; Allele specific; Antisense; Rhodopsin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; RHODOPSIN; MESSENGER RNA;

ALLELE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; ELECTRORETINOGRAPHY; GENE; GENE MUTATION; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; MOUSE; NONHUMAN; PHOTORECEPTOR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINITIS PIGMENTOSA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHODOPSIN GENE; RNA ANALYSIS; TREATMENT RESPONSE; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; MACULAR DEGENERATION; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION; TRANSGENIC RAT;

ALLELES; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; GENE EXPRESSION REGULATION; MACULAR DEGENERATION; MALE; MICE; OLIGONUCLEOTIDES, ANTISENSE; RATS; RATS, TRANSGENIC; REAL-TIME POLYMERASE CHAIN REACTION; RHODOPSIN; RNA, MESSENGER;

EID: 84943553768     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.15-16400     Document Type: Article

References (49)

1. Bird AC. Retinal photoreceptor dystrophies LI. Edward Jackson Memorial Lecture. Am J Ophthalmol. 1995;119:543- 562.
2. Boughman JA, Conneally PM, Nance WE. Population genetic studies of retinitis pigmentosa. Am J Hum Genet. 1980;32: 223-235.
3. Schuster A, Weisschuh N, Jagle H, et al. Novel rhodopsin mutations and genotype-phenotype correlation in patients with autosomal dominant retinitis pigmentosa. Br J Ophthalmol. 2005;89:1258-1264.
4. Sullivan LS, Bowne SJ, Birch DG, et al. Prevalence of diseasecausing mutations in families with autosomal dominant retinitis pigmentosa: a screen of known genes in 200 families. Invest Ophthalmol Vis Sci. 2006;47:3052-3064.
5. Wang DY, Chan WM, Tam PO, et al. Gene mutations in retinitis pigmentosa and their clinical implications. Clin Chim Acta. 2005;351:5-16.
6. Dryja TP, Hahn LB, Cowley GS, McGee TL, Berson EL. Mutation spectrum of the rhodopsin gene among patients with autosomal dominant retinitis pigmentosa. Proc Natl Acad Sci U S A. 1991;88:9370-9374.
7. Dryja TP, McGee TL, Reichel E, et al. A point mutation of the rhodopsin gene in one form of retinitis pigmentosa. Nature. 1990;343:364-366.
8. LaVail MM, Yasumura D, Matthes MT, et al. Protection of mouse photoreceptors by survival factors in retinal degenerations. Invest Ophthalmol Vis Sci. 1998;39:592-602.
9. Chadderton N, Millington-Ward S, Palfi A, et al. Improved retinal function in a mouse model of dominant retinitis pigmentosa following AAV-delivered gene therapy. Mol Ther. 2009;17:593-599.
10. O'Reilly M, Palfi A, Chadderton N, et al. RNA interferencemediated suppression and replacement of human rhodopsin in vivo. Am J Hum Genet. 2007;81:127-135.
11. Mendes HF, Cheetham ME. Pharmacological manipulation of gain-of-function and dominant-negative mechanisms in rhodopsin retinitis pigmentosa. Hum Mol Genet. 2008;17:3043- 3054.
12. Rossmiller B, Mao H, Lewin AS. Gene therapy in animal models of autosomal dominant retinitis pigmentosa. Mol Vis. 2012;18: 2479-2496.
13. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Preservation of photoreceptor morphology and function in P23H rats using an allele independent ribozyme. Exp Eye Res. 2007;84:44-52.
14. Gorbatyuk MS, Pang JJ, Thomas J Jr, Hauswirth WW, Lewin AS. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach. Mol Vis. 2005;11:648-656.
15. Kiang AS, Palfi A, Ader M, et al. Toward a gene therapy for dominant disease: validation of an RNA interference-based mutation-independent approach. Mol Ther. 2005;12:555-561.
16. Mussolino C, Sanges D, Marrocco E, et al. Zinc-finger-based transcriptional repression of rhodopsin in a model of dominant retinitis pigmentosa. EMBO Mol Med. 2011;3:118- 128.
17. Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Mol Ther. 2012;20:699-708.
18. Mao H, James T Jr, Schwein A, et al. AAV delivery of wild-type rhodopsin preserves retinal function in a mouse model of autosomal dominant retinitis pigmentosa. Hum Gene Ther. 2011;22:567-575.
19. Drenser KA, Timmers AM, Hauswirth WW, Lewin AS. Ribozyme-targeted destruction of RNA associated with autosomal- dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 1998;39:681-689.
20. LaVail MM, Yasumura D, Matthes MT, et al. Ribozyme rescue of photoreceptor cells in P23H transgenic rats: long-term survival and late-stage therapy. Proc Natl Acad Sci U S A. 2000;97: 11488-11493.
21. Gorbatyuk M, Justilien V, Liu J, Hauswirth WW, Lewin AS. Suppression of mouse rhodopsin expression in vivo by AAV mediated siRNA delivery. Vision Res. 2007;47:1202-1208.
22. Lewin AS, Drenser KA, Hauswirth WW, et al. Ribozyme rescue of photoreceptor cells in a transgenic rat model of autosomal dominant retinitis pigmentosa. Nat Med. 1998;4:967-971.
23. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu Rev Pharmacol Toxicol. 2010;50:259-293.
24. Gregory E Hardee LGT, Geary. Richard S. Routes and formulations for delivery of antisense oligonucleotides. In: Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press, Taylor and Francis Group; 2008:217-236.
25. Kwoh TJ. An overview of the clinical safety experience of firstand second-generation antisense oligonucleotides. In: Crooke ST, ed. Antisense Drug Technology: Principles, Strategies, and Applications. Boca Raton, FL: CRC Press, Taylor and Group Francis; 2008:365-399.
26. Ostergaard ME, Southwell AL, Kordasiewicz H, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 2013;41: 9634-9650.
27. Henry SP, Miner RC, Drew WL, et al. Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication. Invest Ophthalmol Vis Sci. 2001;42: 2646-2651.
28. Vitravene Study G. Safety of intravitreous fomivirsen for treatment of cytomegalovirus retinitis in patients with AIDS. Am J Ophthalmol. 2002;133:484-498.
29. Lee D, Geller S, Walsh N, et al. Photoreceptor degeneration in Pro23His and S334ter transgenic rats. Adv Exp Med Biol. 2003;533:297-302.
30. Machida S, Kondo M, Jamison JA, et al. P23H rhodopsin transgenic rat: correlation of retinal function with histopathology. Invest Ophthalmol Vis Sci. 2000;41:3200-3209.
31. Cuenca N, Pinilla I, Sauve Y, Lu B, Wang S, Lund RD. Regressive and reactive changes in the connectivity patterns of rod and cone pathways of P23H transgenic rat retina. Neuroscience. 2004;127:301-317.
32. Berson EL, Rosner B, Sandberg MA, Dryja TP. Ocular findings in patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect (Pro-23-His). Arch Ophthalmol. 1991; 109:92-101.
33. Seth PP, Vasquez G, Allerson CA, et al. Synthesis and biophysical evaluation of 2ʹ,4ʹ-constrained 2ʹO-methoxyethyl and 2ʹ,4ʹ-constrained 2ʹO-ethyl nucleic acid analogues. J Org Chem. 2010;75:1569-1581.
34. Orhan EDD, Neuille M, Lechauve C, et al. Genotypic and phenotypic characterization of P23H Line 1 rat model. PLoS One. 2015;10:e0127319.
35. Hung G, Xiao X, Peralta R, et al. Characterization of target mRNA reduction through in situ RNA hybridization in multiple organ systems following systemic antisense treatment in animals. Nucleic Acid Ther. 2013;23:369-378.
36. Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington's disease by transient repression of huntingtin synthesis. Neuron. 2012;74:1031- 1044.
37. Bayer AU, Mittag T, Cook P, Brodie SE, Podos SM, Maag KP. Comparisons of the amplitude size and the reproducibility of three different electrodes to record the corneal flash electroretinogram in rodents. Doc Ophthalmol. 1999;98: 233-246.
38. LaVail MM, Battelle BA. Influence of eye pigmentation and light deprivation on inherited retinal dystrophy in the rat. Exp Eye Res. 1975;21:167-192.
39. Faktorovich EG, Steinberg RH, Yasumura D, Matthes MT, LaVail MM. Photoreceptor degeneration in inherited retinal dystrophy delayed by basic fibroblast growth factor. Nature. 1990; 347:83-86.
40. Michon JJ, Li ZL, Shioura N, Anderson RJ, Tso MO. A comparative study of methods of photoreceptor morphometry. Invest Ophthalmol Vis Sci. 1991;32:280-284.
41. Geary RS, Leeds JM, Henry SP, Monteith DK, Levin AA. Antisense oligonucleotide inhibitors for the treatment of cancer: 1. Pharmacokinetic properties of phosphorothioate oligodeoxynucleotides. Anticancer Drug Des. 1997;12:383- 393.
42. Yu RZ, Grundy JS, Geary RS. Clinical pharmacokinetics of second generation antisense oligonucleotides. Expert Opin Drug Metab Toxicol. 2013;9:169-182.
43. Butler M, Stecker K, Bennett CF. Cellular distribution of phosphorothioate oligodeoxynucleotides in normal rodent tissues. Lab Invest. 1997;77:379-388.
44. Wen Y, Klein M, Hood DC, Birch DG. Relationships among multifocal electroretinogram amplitude, visual field sensitivity, and SD-OCT receptor layer thicknesses in patients with retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2012;53: 833-840.
45. Wong LL, Pye QN, Chen L, Seal S, McGinnis JF. Defining the catalytic activity of nanoceria in the P23H-1 rat, a photoreceptor degeneration model. PLoS One. 2015;10:e0121977.
46. Frederick JM, Krasnoperova NV, Hoffmann K, et al. Mutant rhodopsin transgene expression on a null background. Invest Ophthalmol Vis Sci. 2001;42:826-833.
47. Olsson JE, Gordon JW, Pawlyk BS, et al. Transgenic mice with a rhodopsin mutation (Pro23His): a mouse model of autosomal dominant retinitis pigmentosa. Neuron. 1992;9:815-830.
48. Price BA, Sandoval IM, Chan F, et al. Rhodopsin gene expression determines rod outer segment size and rod cell resistance to a dominant-negative neurodegeneration mutant. PLoS One. 2012;7:e49889.
49. O'Connor TP, Crystal RG. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet. 2006;7: 261-276.